We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
The Advisory Council on the Misuse of Drugs has been asked to consider the appropriate scheduling of cannabis-related products.
First published during the 2016 to 2019 May Conservative government
Letter to the Home Secretary from the chair of the Advisory Council on the Misuse of Drugs, outlining their work programme for 2016.
Lynne Featherstone writes to the chair of Advisory Council on the Misuse of Drugs (ACMD) on health practitioners independent prescribing.
Funding cuts are the single biggest threat to drug treatment recovery outcomes, a report published by the ACMD has warned.
The government commissions the Advisory Council on the Misuse of Drugs (ACMD) to review the harms of Xylazine and 2-Methyl-AP-237.
First published during the 2022 to 2024 Sunak Conservative government
The Advisory Council on the Misuse of Drugs (ACMD) has published a report reviewing the availability and use of naloxone in the UK, a drug used to reverse opioid overdose.
Forms for members of the public to provide written evidence on young people’s drug use and naloxone provision.
Letter to the Home Office regarding the appropriate Schedule for the cannabis-based product for medicinal use, Epidyolex, under the Misuse of Drugs Regulations 2001.
Sets out how our obligations relating to the management of personal data will be addressed by the civil servants that support the ACMD in the Home Office Science Secretariat (HOSS).
Further advice about the prescribing of controlled drugs by therapeutic radiographers.
The Advisory Council on the Misuse of Drugs has provided an updated harms assessment of alkyl nitrites.
Quality of treatment for heroin users under threat from shrinking resources and disruptive re-procurement processes.
Independent report by the Advisory Council on the Misuse of Drugs (ACMD) investigates the risk factors to substance use-related problems and harms.
Further advice from the Advisory Council on the Misuse of Drugs (ACMD) to the Home Office about the scheduling of cannabis-derived medicinal products.
Barriers to Research working group calls for written evidence about barriers to legitimate research for controlled drugs, excluding synthetic cannabinoids.
Provides a summary of the main issues the ACMD considered between January 2017 and December 2019.
ACMD public request for written evidence on cognition enhancers (also known as ‘nootropics’ or ‘study drugs’).
Further letter from the Advisory Council on the Misuse of Drugs about U-47,700 and designer benzodiazepines.
The ACMD’s response to correspondence from the Department of Health, Social Services and Public Safety (DHSSPS) in relation to Northern Ireland’s continued maintenance of the Addicts Index.
The ACMD is holding a public evidence gathering day on Image and Performance Enhancing Drugs on Tuesday 26 September at The Kia Oval, Vauxhall, London.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).